Background: Onset during old age has been reported in upto 10% of total cases of
| INTRODUCTION

Inflammatory bowel disease (IBD) is a chronic intestinal disorder
whose clinical presentation usually occurs in childhood or young adulthood. Although the diagnosis of IBD among children has increased in recent years, [1] [2] [3] [4] population-based studies report that up to 10% of new cases of IBD are diagnosed in the elderly population. [5] [6] [7] [8] [9] [10] The Montreal classification of Crohn's disease (CD) classifies patients in terms of age at disease diagnosis in the following groups:
less than 17, 17 to 40, and over 40 years of age. 11 The rising incidence of paediatric IBD, together with a better knowledge of its phenotypic features and prognosis, led paediatricians to pose a new classification of IBD in children taking into account those cases with very early disease onset, among other aspects. 12 No similar changes have so far been considered for adults. Uncertainties regarding clinical presentation, disease course, and the impact of treatments on elderly onset IBD still exist due to limited data availability.
Current trends in IBD recommend an initially more intensive medical approach with the aim of preventing disease progression and avoiding surgery. [13] [14] [15] However, in patients older than 65 years, a gentler approach might be considered because of the higher risk of infectious and neoplastic complications associated with the use of immunosuppressive agents. [16] [17] [18] [19] [20] In addition, elderly patients, as well as patients with comorbidities (a common situation in elderly patients), are systematically excluded from randomised controlled studies. Furthermore, surgical outcomes in elderly patients may differ from those of younger ones, 21, 22 and early surgical interventions have been advised in elderly patients to avoid complications related to delayed surgery. 22 For all of these reasons, an accurate assessment of the phenotypical presentation, clinical course and treatment-related complications in elderly onset IBD is warranted.
The aims of the present study were to compare the phenotypic characteristics, the use of therapeutic resources, and the clinical outcomes between patients with elderly onset IBD with those with disease onset in young adulthood.
| PATIENTS AND METHODS
This was an observational, retrospective, case-control, multicentre study, promoted by the Spanish Working Group in IBD (GETECCU), and was performed in 29 Spanish hospitals. The study was approved by the local Ethics Committees of all the participating centres.
| Patient population
All patients diagnosed with IBD over the age of 60 (elderly onset) from January 2000 to December 2012 were identified from the IBD databases at each participating centre. Elderly onset cases were included if they were diagnosed with IBD and followed-up for at least 12 months at the same center. For the purposes of our study, each case was matched by year of diagnosis, gender, type of IBD, and center with a patient diagnosed with IBD between 18 and 40 years of age (adult-onset). 
| Description of variables
| RESULTS
We identified a total of 1374 elderly onset IBD patients, representing 11% of the incident IBD patients in the participating centers during the study period. The baseline characteristics of the study population are summarised in Table 1 . Almost two-thirds of elderly onset patients were UC. Both study cohorts differed in the mean follow-up time, which was significantly shorter among elderly onset patients (55 vs 81 months, P = 0.03) since these patients showed higher rates of loss to follow-up and death (12.8% vs 7%; P < 0.0001, and 9.5% vs 0.09%; P < 0.0001, respectively).
| IBD phenotype and disease-related complications
The main phenotypic features are summarised in Table 2 . In UC, leftsided UC was significantly more prevalent whereas the prevalence of extensive UC and ulcerative proctitis was lower in elderly onset as compared to adult-onset patients. It is also noteworthy that the rate of proximal spread of the disease was identical in both groups (8%).
Regarding CD, a significantly higher proportion of exclusive colonic involvement was observed in elderly onset patients. Elderly onset patients had a higher risk of developing strictures and a lower risk of penetrating complications and perianal disease over time than adultonset patients.
Extraintestinal manifestations were slightly more frequent among adult-onset patients, mainly because of joint manifestations. In contrast, we found a fivefold higher prevalence of thrombotic events among elderly onset patients.
| IBD therapy and surgery
The use of therapeutic resources in both groups is summarised in Figure 1 . Although in UC, corticosteroids were given in a similar proportion to elderly onset and adult-onset patients, there was a significantly lower rate of steroid-dependency among elderly onset patients (14% vs 22%; P < 0.0001). Also in UC, immunosuppressants and biological agents were both given in a lower proportion to elderly onset patients. The cumulative probability of starting on immunosuppressants was 15% and 36% in elderly onset and 27%
and 53% in adult-onset patients at 1 and 5 years respectively (P < 0.0001). The cumulative probability of receiving anti-TNF alpha agents was 2% and 7% in elderly onset and 2% and 10% in adultonset patients at 1 and 5 years respectively (P < 0.0001) ( Figure 2 ).
In CD, there was a significantly lower use of corticosteroids, immunosuppressants and anti-TNF alpha agents in elderly onset patients than in adult-onset. A significantly lower rate of steroiddependency (21% vs 30%; P < 0.001) and steroid-refractoriness (8% vs 6%; P < 0.006) was observed among elderly onset patients. The cumulative probability of starting on immunosuppressants in CD was 28% and 57% in elderly onset and 48% and 80% in adult-onset patients at 1 and 5 years respectively (P < 0.0001) ( Figure 3) . Most of the patients using immunosuppressants were treated with thiopurines (92% of elderly onset patients and 94% of adult-onset), and only a small proportion received methotrexate (4% of elderly onset patients and 6% of adult-onset). The cumulative probability of starting anti-TNF alpha agents was 5% in elderly onset patients and 10%
in younger onset at 1 year, and 12% and 14% at 5 years respectively (P = 0.005) (Figure 3 ).
Regarding intestinal surgery, there was a similar rate of surgeries in both groups in CD. Conversely, in UC, there was a significantly higher colectomy rate among elderly onset patients (P < 0.009). The cumulative probability of surgery in CD was 25% for elderly onset patients and 17% for adult-onset at 1 year, and 36% and 29% at 5 years (P = 0.17), respectively. In UC, the cumulative probability of surgery was 4% for elderly onset patients and 4% for adult-onset at 1 year, and 11% and 5% at 5 years respectively (P = 0.01) (Figure 4 ).
No differences were found between study groups regarding post- Regarding adverse events (AE), there was a higher incidence of thiopurine-related AE in elderly onset patients than in adult-onset (46% vs 32%, P = 0.001), mainly related to a higher incidence of myelotoxicity (anaemia, aplasia) and hepatotoxicity (Table 3 ). In contrast, no differences were observed in the incidence of AE due to anti-TNF alpha agents (23% vs 21%). However, elderly onset patients had more infections associated with anti-TNF alpha therapies and less acute infusion reactions (Table 3) . In elderly onset patients, 42% of the infections related to anti-TNF alpha agents were severe (requiring hospital admission or leading to death) while that rate was only 30% in younger-onset (P = 0.28). Most of the patients with infections related to anti-TNF alpha therapy were on concomitant immunosuppressants.
In the logistic regression analysis, elderly onset of IBD was independently associated with a lower use of immunosuppressants (OR = 0.311, 95% CI = 0.23-0.42; P < 0.0001) and anti-TNF alpha agents (OR = 0.54, 95% CI = 0.39-0.75; P < 0.05).
| Hospital admissions, neoplasms and mortality
Elderly onset patients had a higher rate of hospital admissions (P = 0.022) than adult-onset patients (Table 4) , though active disease and onset of the disease were the more frequent causes of admission in both groups. This difference was due to a higher rate of hospital admissions not related to IBD among elderly onset patients.
Moreover, elderly onset patients had longer hospital stays (13 AE 12.9 vs 8 AE 11.9 days; P = 0.05).
As expected, deaths were more frequent among elderly onset patients (112 patients 8% vs 1 patient 0.07%; P < 0.0001), and this was also regarding only IBD-related deaths (10% vs 0%; P < 0.0001)). this perspective, one of the methodological issues when this study was designed was the cut-off age for the definition of elderly onset of IBD. The age of 60 or 65, roughly equivalent to retirement ages in most developed countries, is considered to be the beginning of old age. The reason for choosing 60 years in our study was that this was the cut-off in most studies with similar aims. 5, 10, [23] [24] [25] In line with this, the estimated frequency of elderly onset IBD in our study is 11%, which is very close to the 10%-23% reported in other European studies. 5, 7, 8, 10, 23 Similarly, another key issue was the age segment of the comparison cohort. We decided to choose those patients with disease onset between 18 and 40 years, which is the most frequent one, in analogy to the A2 group of the Montreal classification. Our study therefore disregards those patients with a disease onset between 40 and 60 years of age, which could be considered a limitation but might also increase differences with respect to the elderly onset group.
| DISCUSSION
In agreement with recent data, 5, 23, 24 our study shows that elderly onset IBD patients develop a less aggressive phenotype. When compared to adult-onset patients, elderly onset CD showed a greater degree of stricturing behaviour and a greater proportion of isolated colon disease. 5, 24 Elderly onset UC patients showed a predominance
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Younger-onset patients (n = 232) (%) P of left-sided colitis as in previous studies. 5, 10, 23 Conversely, we did not observe a lower risk of proximal spread in elderly onset UC as it has been reported in other studies. 10 Although we do not have a clear explanation for this finding, the relatively short follow-up period may account for the low proximal progression rate in our cohorts. Thus, the less aggressive phenotype of elderly onset IBD suggests that the stepup algorithm is more suitable in this subgroup of patients.
As mentioned previously, older age is often associated with comorbidities and polypharmacy, leading to a higher risk of drug interactions and drug-related adverse events and, probably, to a delay in treatment escalation. 22 Although no study has compared the use of therapeutic resources in elderly onset IBD patients and longstanding IBD elderly patients, there are a small number of comparative studies of this topic in elderly onset IBD patients and young IBD patients, including a population-based study from The Netherlands 10 and a small, retrospective, American case-control study of CD patients. 24 To our knowledge, our study is the largest one that has compared the use of therapeutic resources and drug-related adverse events in elderly onset and younger patients. Contrarily to previous studies, [26] [27] [28] [29] [30] we found a similar rate of corticosteroid use among study elderly onset and adult-onset IBD patients, but in agreement with previously reported data in long-lasting IBD elderly patients, 5,31-33 we found a lesser use of immunosuppressants and anti-TNF agents in elderly onset patients. This may not be due only to fear of the development of adverse events 34 (mainly serious infections and non-Hodgkin lymphoma) 35, 36 but also to a milder form of the disease. However, this finding might be also mean a suboptimal use of medical therapies in elderly.
The safety profile of thiopurines and anti-TNF agents has been scarcely assessed comparing age segments and only a higher rate of serious adverse events (particularly those requiring hospital admission and those leading to death) has been reported among elderly patients. 16, 19 We found a significantly higher rate of thiopurinerelated adverse events and also a different profile of anti-TNFrelated adverse events in elderly onset patients. A plausible explanation for this differences on anti-TNF safety profile might be the role of immunosenescence, [37] [38] [39] [40] leading to a higher likeliness for severe infections but a lower tendency to immune-mediated reactions. Our results, together with the increased risk of thiopurine-related lymphoma, could be the argument for the use of anti-TNF monotherapy in those elderly patients in whom immunosuppression is indicated.
Recent studies reported a similar rate of surgery among elderly onset IBD patients and younger patients. 5, 10, [23] [24] [25] [41] [42] [43] [44] In our series, CD patients had a similar rate of surgery in both groups. However, in UC, there was a significantly higher surgery rate in elderly onset patients. Moreover, when looking at the survival curves, there was a steady risk of surgery over time among elderly onset patients, whereas adult-onset UC patients were mainly operated on within the first years after diagnosis. These findings suggest that clinicians are less likely to prescribe immunosuppressants and anti-TNF alpha anti-TNF alpha agents and refer elderly UC patients for surgery more frequently. Although age is a relevant risk factor for post-operative complications, 23 ,45 the rate of post-operative complications was similar in both study cohorts. This may be due, at least in part, to the improved rate of post-operative complications in elderly patients in recent years 23 as a consequence of a better medical management, improving nutritional status and a trend to earlier surgery. 46, 47 Taken altogether, our results support that timely proctocolectomy should be considered as a real alternative to thiopurines and anti-TNF in elderly onset UC. Conversely, in CD, a similar treatment algorithm should be followed in elderly and adult patients, as surgery is not curative and thiopurines and anti-TNF agents are often use in the post-operative setting for the prevention or treatment of postoperative recurrence. 48 The strengths of our study are its comparative-matched cohort, its large sample size and the availability of data on main IBD medications, surgery and hospital admissions. However, there are several limitations to our study. First, its retrospective, hospital-based (not population-based) design might account for some biases. Secondly, imaging and endoscopic data, mucosal healing rates and serum or faecal biomarkers are lacking due to the study's retrospective nature, which hampered the collection of these data for most patients at particular time points. Finally, we were not able to collect the cumulative prednisone dose and concomitant medication beyond IBD, which may have impacted some long-term outcomes.
In conclusion, our study confirms that elderly onset IBD is associated with a less aggressive phenotype, by means of a lower proportion of small bowel location and penetrating behaviour in CD and higher proportion of left-sided UC. Interestingly, we also found that drug-related side effects seem to be different in elderly patients, an issue that should be further confirmed and taken into account in therapeutic decision-making. Our results suggest that elderly onset CD should be treated following a nuanced approach whereas, in elderly onset UC, surgery should be considered as a real alternative to immunosuppression.
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